Prostate Cancer Clinical Trial
Official title:
A Randomized Phase II Study of a PSA-Based Vaccine in Patients With Localized Prostate Cancer Receiving Standard Radiotherapy
This study will test the ability of an experimental vaccine to increase the number of
tumor-fighting immune cells (lymphocytes) in patients with localized prostate cancer and
prevent the disease from recurring following radiation therapy. The vaccine is intended to
stimulate lymphocytes to target and attack cells containing a protein called prostate
specific antigen, or PSA. It is composed of the following parts:
- rV-PSA: Vaccinia virus plus human DNA that produces PSA (prostate specific antigen)
- rV-B7.1: Vaccinia virus plus human DNA that produces B7.1 (a protein that helps guide
immune cells to their targets)
- rF-PSA: Fowlpox virus plus human DNA that produces PSA
- GM-CSF: Drug that boosts the immune system.
- IL-2: Drug that boosts the immune system.
Patients 18 years of age and older with prostate cancer confined to the prostate who have
received a smallpox vaccine sometime in the past and who do not have a history of allergy to
eggs may be eligible for this study. Candidates are screened with a complete medical history
and physical examination, blood tests, and skin tests (similar to those for allergies or
tuberculosis) to assess immune function.
Participants are randomly assigned to receive one of the following three treatments: Group 1
- standard radiation therapy plus the experimental vaccine; Group 2 - standard radiation
therapy without the vaccine; Group 3 - standard radiation therapy with the vaccine, but with
a different dose of IL-2 from Group 1.
Patients in the vaccine groups receive injections in the arm or thigh in 28-day treatment
cycles, as follows:
- GM-CSF: Days 1 through 4 of the first week
- IL-2 5: for Group 1, 5 days in the second week of each cycle; for Group 3, 14 days
beginning in the second week of each cycle
- rV-PSA and rV-B7.1: Day 2 of the first cycle only
- rF-PSA (booster shots): Every 28 days, beginning day 2 of the second cycle (i.e., days
30, 58, 86, etc.)
Treatment continues for eight cycles unless serious side effects develop, PSA levels rise
significantly, or the doctors feel there is no reason to continue therapy.
All patients undergo radiation therapy and possibly hormone therapy, if indicated. Blood
samples are drawn once a week for the first month and then once every 4 weeks to monitor
safety. After treatment ends, patients are followed with examinations and blood tests every 3
months for the first 2 years and then every 6 months until the doctors determine follow-up is
no longer needed or the cancer returns.
All patients have HLA tissue typing at the beginning of the study. Those who are type HLA-A2
are asked to have additional procedures for studying the immune response that can be done
only with this tissue type. This involves collecting blood samples before treatment begins,
every 4 weeks during treatment, once after cycle 2, and once 4 months after the eighth
vaccine. They also undergo four leukapheresis procedures for collecting white blood cells.
For leukapheresis, blood is collected through a needle in an arm vein, similar to donating a
unit of blood. The blood flows through a machine that separates it into its components. The
white cells are removed, and the red cells, platelets and plasma are returned to the body,
either through the same needle or through a needle in the other arm.
This trial will evaluate the immunologic effects of a vaccination regimen in HLA-A2 positive
prostate cancer patients. Eligible patients will have localized prostate cancer and be
willing to undergo definitive local radiotherapy. 30 patients will be randomized in a 2:1
ratio into two cohorts (see schema below) with patients in the vaccine arm receiving
vaccination before, during and after primary standard radiotherapy (external beam alone or in
combination with brachytherapy). When enrollment to these two cohorts is complete, enrollment
will begin with up to 19 (9-10 HLA-A2 positive) patients to a third, non-randomized vaccine
cohort. This cohort C will differ from the first vaccine cohort only in the IL-2 dose and
schedule. The vaccine regimen will be composed of (1) a recombinant vaccinia virus that
expresses the Prostate Specific Antigen gene (rV-PSA), admixed with (2) a recombinant
vaccinia virus that expresses B7.1 costimulatory molecule (rV-B7.1); followed by (3)
sequential vaccinations with recombinant fowlpox virus containing the PSA gene (rF-PSA). All
patients on the vaccine arms will, in addition, receive sargramostim and aldesleukin as part
of their vaccination schedule.
The primary endpoint is to identify immunologic response as measured by in vitro analysis of
the patients peripheral blood cells. The immune response of cohorts A and B will be analyzed
at various times to determine whether a specific immune response can be affected by the
vaccination as well as whether radiotherapy has an effect on that immune response. The serum
PSA will be followed as a secondary endpoint.
All patients with PSA-expressing adenocarcinoma of the prostate will be evaluated for
eligibility that includes a history of prior vaccinia (as vaccine against smallpox) and
immunocompetence.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |